State Street SPDR S&P Pharmaceuticals ETF

XPH

Market cap $233M

As big pharmaceutical companies are set to finalize a deal with the U.S. government to bring down prices for some prescription drugs, another old question is coming into focus for investors: how much damage can Washington really do to Big Pharma's bottom line?

Worried about high valuations? KBE, XRT, and XPH with low P/Es and fresh momentum are three undervalued ETFs to consider as 2026 approaches.

For investors seeking momentum, State Street SPDR S&P Pharmaceuticals ETF XPH is probably on the radar. The fund just hit a 52-week high and rose 61.4% from its 52-week low price of $35.22/share.

The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.

The US has agreed to spare the UK from threatened trade tariffs on pharmaceutical products.

Agreement also calls for NHS to increase net price it pays for new medicines by 25%

Britain and the United States are poised to agree to zero tariffs on pharmaceutical products, with an announcement due at the White House on Monday, according to two sources familiar with the matter.

The UK is poised to agree on a major pharmaceuticals deal with the U.S., which will mean zero import tariffs on pharmaceutical products into the U.S. and lead to an increase in NHS spending on medicines, The Times reported on Monday.

Launched on June 19, 2006, the State Street SPDR S&P Pharmaceuticals ETF (XPH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.

A smart beta exchange traded fund, the State Street SPDR S&P Pharmaceuticals ETF (XPH) debuted on 06/19/2006, and offers broad exposure to the Health Care ETFs category of the market.